Skip to main content
. Author manuscript; available in PMC: 2015 Sep 18.
Published in final edited form as: Chem Biol. 2014 Sep 18;21(9):1102–1114. doi: 10.1016/j.chembiol.2014.09.001

Figure 2.

Figure 2

Peptide-like inhibitors of PPI with primary epitopes. A) SAR1 118 (lifitegrast) inhibits binding of LFA1 (CD11a/CD18) to its ligand ICAM. The mechanism either involves binding directly to the ICAM site in the I-domain of CD11a (Keating et al., 2006) or allosteric inhibition through binding to the I-like domain in CD18 (Shimaoka et al., 2003). B) X-ray structure of a cIAP1/XIAP chimera (white surface) bound to GDC-0152 (green sticks; PDB: 3UW4) and overlaid with SMAC peptide (magenta cartoon; PDB: 1G73). Chemical structures of SMAC mimetics in clinical trials.